Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb 5;129(3):326-31.
doi: 10.4103/0366-6999.174503.

Role of Circulating Fibrocytes in Cardiac Fibrosis

Rong-Jie Lin, Zi-Zhuo Su, Shu-Min Liang, Yu-Yang Chen, Xiao-Rong Shu, Ru-Qiong Nie, Jing-Feng Wang, Shuang-Lun Xie  1
Affiliations
Review

Role of Circulating Fibrocytes in Cardiac Fibrosis

Rong-Jie Lin et al. Chin Med J (Engl). .

Abstract

Objective: It is revealed that circulating fibrocytes are elevated in patients/animals with cardiac fibrosis, and this review aims to provide an introduction to circulating fibrocytes and their role in cardiac fibrosis.

Data sources: This review is based on the data from 1994 to present obtained from PubMed. The search terms were "circulating fibrocytes " and "cardiac fibrosis ".

Study selection: Articles and critical reviews, which are related to circulating fibrocytes and cardiac fibrosis, were selected.

Results: Circulating fibrocytes, which are derived from hematopoietic stem cells, represent a subset of peripheral blood mononuclear cells exhibiting mixed morphological and molecular characteristics of hematopoietic and mesenchymal cells (CD34+/CD45+/collagen I+). They can produce extracellular matrix and many cytokines. It is shown that circulating fibrocytes participate in many fibrotic diseases, including cardiac fibrosis. Evidence accumulated in recent years shows that aging individuals and patients with hypertension, heart failure, coronary heart disease, and atrial fibrillation have more circulating fibrocytes in peripheral blood and/or heart tissue, and this elevation of circulating fibrocytes is correlated with the degree of fibrosis in the hearts.

Conclusions: Circulating fibrocytes are effector cells in cardiac fibrosis.

PubMed Disclaimer

References

    1. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79:215–62. - PubMed
    1. Burstein B, Nattel S. Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802–9. doi: 10.1016/j.jacc.2007.09.064. - PubMed
    1. McArthur L, Chilton L, Smith GL, Nicklin SA. Electrical consequences of cardiac myocyte: Fibroblast coupling. Biochem Soc Trans. 2015;43:513–8. doi: 10.1042/bst20150035. - PubMed
    1. Hao PP, Yang JM, Zhang MX, Zhang K, Chen YG, Zhang C, et al. Angiotensin-(1-7) treatment mitigates right ventricular fibrosis as a distinctive feature of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2015;308:H1007–19. doi: 10.1152/ajpheart.00563.2014. - PubMed
    1. Hao P, Yang J, Liu Y, Zhang M, Zhang K, Gao F, et al. Combination of angiotensin-(1-7) with perindopril is better than single therapy in ameliorating diabetic cardiomyopathy. Sci Rep. 2015;5:8794. doi: 10.1038/srep08794. - PMC - PubMed

Publication types